DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index A Acute radiation injury, 143, 152 AA amyloidosis, 132 Adalimumab, 73, 76 AAC, see Antibiotic-associated colitis (AAC) ADAMTS-13, 44 AAHC, see Antibiotic-associated Addison’s disease (AD), 370–371 hemorrhagic colitis (AAHC) causes and clinical features, 370 Abdominal cramps, 7, 17, 21, 43, 45, 47, 228, gastrointestinal symptoms, 371 282, 301, 327, 417 treatment, 371 Abdominal distension, 45, 83, 144, 215, Adenosine triphosphate (ATP), 10 328, 344 Adrenal gland, 370–373 Abdominal pain, 9, 17, 35, 40, 44, 46–53, 65, Adult-type hypolactasia, 159, 163–164 67, 69, 77, 81, 83–84, 95, 109–110, 131, Adverse reactions to food, 106–107 142–144, 151, 160, 162, 166, 168, 194, Aerobic organisms, 191 213, 215, 241–242, 244–245, 248, Aeromonas hydrophila, 47 253–257, 267, 276, 312, 318, 321, AIDS, see Acquired immunodeficiency 325–326, 328–329, 333–336, 342–343, syndrome (AIDS) 345, 347, 350, 364, 371, 385, 434, 449 Albendazole, 41, 49 Abdominal X-rays, 87 Albumin, 68, 108, 118–120, 122–123, Abetalipoproteinemia, 159, 169–171 125–126, 128, 130–134, Absorption, see Congenital disorders of 153, 345 digestion and absorption Alcohol-related diarrhea, 379–387 Acanthocytosis, 170 absorption and metabolism of alcohol in Acetorphan, 398 gut, 381 Acetylcholine, 12, 178, 352, 403–404 “bacteriocolonic” pathway of ethanol Acetylcholinesterase inhibitors, 396, 404 oxidation, 381 Acetylsalicylic acid, 198 concentration of acetaldehyde, 381 Achlorhydria, 192, 248, 259, 267, 272 ethanol absorption, 381 Acid-tolerant aerobic organisms, 191 first-pass metabolism, 381 Acquired immunodeficiency syndrome gastrointestinal neuromuscular (AIDS), 6, 51, 121, 368, 414, 453, 466 injury, 381 Acrodermatitis enteropathica (AE), 172–173 mucosal permeability, 381 Actinobacter, 227 non-oxidative metabolism, 381 Acute diarrhea classification, 380–381 community-acquired, 4–6 alcohol hangover (veisalgia), 381 diagnosis, 20 alcohol-related organ dysfunction, 381 hospital-acquired, 6–7 alcohol withdrawal, 380 traveler’s, 7–8 concurrent dietary indiscretion, 380 Acute gastroenteritis, 8, 290, 295, 349 clinical presentation, 381–386 Acute mesenteric ischemia (AMI), 251–253 alcohol hangover or veisalgia, 385 Acute proctosigmoiditis, 416 alcohol-induced organ dysfunction, 385 From: Diarrhea, Clinical Gastroenterology Edited by: S. Guandalini, H. Vaziri, DOI 10.1007/978-1-60761-183-7 C Springer Science+Business Media, LLC 2011 475 476 Subject Index Alcohol-related diarrhea (cont.) Antibiotic-associated colitis (AAC), 48, 398 alcohol withdrawal syndrome Antibiotic-associated hemorrhagic colitis (AWS), 385 (AAHC), 47 binge drinking, 381–385 Antibiotics chronic alcoholics, 385 in bacterial overgrowth, 198–201 toxic alcohol-induced diarrhea, 385 drug-induced diarrhea, 412–413 etiopathogenesis, 381–386 in IBD, 74 pathophysiology of acute in IBS, 336 alcohol-induced diarrhea, 382–383 prevention of, associated diarrhea, 465 pathophysiology of chronic in radiation enterocolitis, 151 alcohol-induced diarrhea, 383–384 Antibodies, 73, 75–76, 96, 108, 112, 129, 131, treatment, 386–387 172, 219, 247, 249, 330, 345, 361–362, acute alcohol-related diarrhea, 386 366, 372 antibiotics, 387 Anticholinergics, 131, 333–334, 352–353, benzodiazepines, 387 396, 404, 406, 443, 448, 452–453 cholestyramine, 387 Antidepressants, 334 chronic alcohol-related diarrhea, amitriptyline, 334 386–387 desipramine, 334 clonidine, 387 fluoxetine, 334 niacin and oral vitamin C, 387 imipramine, 334 thiamine, 386 nortriptyline, 334 ursodeoxycholic acid, 387 paroxetine, 334 Allergic gastroenteropathy, 123 serotonin reuptake inhibitors (SSRI), 334 Allergy, 20, 87, 105–115, 220, 332, 394–395 sertraline, 334 Allopurinol, 416 tricyclic antidepressants (TCA), 334 Alopecia, 172, 218 Antidiarrheal agents, 53, 78, 151, 335, Alpha 1-antitrypsin, 114, 128–130 399, 417 Alpha 2-adrenergic agonist, 367, 443, 453 Anti-endomysial IgA antibody Alzheimer’s disease, 404 (EMA-IgA), 219 Amebic colitis, 6, 21 Anti-endomysium antibodies, 219 American Academy of Microbiology report, 2 Anti-inflammatory agents, 20, 114, 202, 255 Amifostine, 149–150 Antimotility agents, 44, 53, 290, 364 Amino acids, 10, 118–120, 124, 165, Antiplasmin therapy, 132 167–169, 172, 274–275, 287, 382, 384 Antiretroviral therapy, 50, 396, 398–399 Aminoglycosides, 46, 231, 399 Anti-social personality disorder, 300 Aminosalicylates, 62, 65, 74, 76, 99, 247, 396 Antispasmodic agents, 333 5-Aminosalicylic acid (5-ASA), 149 Anti-tissue transglutaminase IgA (TTG-IgA), 5-Aminosalicylate (5-ASA), 65, 149–150 96, 219, 222, 319 Amitriptyline, 334 APOB gene, 161, 170 Amoxicillin, 74, 199, 412 Apolipoprotein B, 161, 170–171 Ampicillin, 39, 232, 412 Appendectomy, 242–245 Amyloidosis, 11, 16, 121, 132, 315, 435, 440 Appendicitis, 41, 46, 84, 111, 239, Anaerobic organisms, 191, 196, 364 243–245, 293 Anemia, 23, 49, 67–68, 96, 110–111, APS, see Autoimmune polyglandular 122–123, 131, 145, 160, 169, 193, syndromes (APS) 215–216, 226, 248, 251, 267, 274, 329, Aquaporins (AQP), 283, 286, 289 345, 360, 364–365, 371–373, 436 Arf6 endocytic pathway, 286 Anorectal dysfunction and incontinence, 364 Arthralgias, 38, 51, 95, 97, 216, 228–229 anal sphincter dysfunction, 364 Arthritis, 41, 46–47, 67, 95, 190, 193, 216, fecal incontinence, 364 225–226, 229–230, 416 sphincter dysfunction, 364 Aspirin therapy, 348 Antacids, 19–20, 306, 330, 397, 402, 412 Athletes’ GI symptoms, 427–428 Anthraquinones, 300, 304–307, 403 Atropine, 98, 410, 417, 451–453 Subject Index 477 Attapulgite, 447–448 Balantidium coli, 49 Atypical celiac disease with extraintestinal Balsalazide, 149–150 manifestations Barium enema, 70, 94, 146–148, 239 arthritis and arthralgia, 216 Barium X-ray, 129 chronic hepatitis and Benign conditions, 112, 125, 332, 345, 351 hypertransaminasemia, 216 Benzodiazepines, 335, 386–387 dental enamel hypoplasia, 216 Beta blockers, 370 dermatitis herpetiformis, 215–216 Beta cells, 167 iron deficiency anemia, 216 Beta-fructofuranoside fructohydrolase, neurological manifestation, 217 165, 352 osteopenia/osteoporosis, 217 Bethanecol, 403 psychiatric disorders, 217 Bifidobacteria, 77, 191, 198, 461, 465 short stature and delayed puberty, 216 Bilateral retinal detachments, 122 Auranofin, 399, 416 Bile acid breath test, 360 Autoantibody testing, 129 Bile acid deficiency, 145, 171, 380, 386 Autoimmune disorders, 95–96, 210, 218 Bile acid diarrhea, 13, 145, 152, 349, 383, Autoimmune polyglandular syndromes 386–387 (APS), 371–373 Bile acid malabsorption, 97, 159, 171, type I, 371–372 311–312, 315, 348–349, 353, 360, 366, autoimmune hypoparathyroidism, 371 369–370, 380, 383, 386, 408–409, autoimmune regulator (AIRE) gene, 371 439–441, 450 cholecystokinin deficiency, 372 Bile salt, 12–13, 15, 64, 66, 77, 169, 171, 246, lymphangiectasia, 372 347, 349, 353, 383, 387, 405–406 muco-cutaneous candidiasis, 372 Bile salt-induced diarrhea, 12, 66, 246, superimposed Giardia infection, 372 347, 387 type II, 372–373 Biliary tract disease, 47 myasthenia gravis, 372 Biofeedback, 336, 366 primary hypogonadism, 372 Biomarkers, 85, 89, 272 Autoimmune regulator (AIRE) gene, 371 Biopsy, 40, 47–49, 69, 71, 87, 95, 111, 124, Autonomic neuropathy, 11, 19, 315, 142, 195, 198, 219, 230–232, 240, 249, 362–364, 367 255, 318–319, 321, 330, 345, 360–363, Azathioprine, 73, 75, 99, 124, 373 366, 439 Azithromycin, 38, 42–44, 47, 54, 291–292 Bisacodyl, 304, 306–308, 403 Azotorrhea, 182 Bismuth subsalicylate, 53–54, 98, 398, 417, 447, 449–450 B Blastocystis hominis, 6, 49 Bacillus cereus, 282, 294 Bloating, 23, 39, 64, 77, 83–84, 90, 151, Bacterial overgrowth, 189–203, 363, 380 193–194, 201, 215, 218, 228, 276, 327, clinical conditions 333, 336–337, 426, 449, 454 gastroesophageal reflux, 195 Blood–brain barrier, 231, 451–452 inflammatory bowel disease, 195 Bloody diarrhea, 5, 17, 41, 45–47, 53–54, 65, irritable bowel syndrome, 194–195 144, 239–240, 242, 252, 301 short bowel syndrome, 194 Bone marrow 14C xylose breath test, 364 biopsy, 240, 249 defined, 192 transplantation, 125, 249, 373 diagnosis, 195–198 Bowel dilation, 202 mechanisms, 192–193 Bowel obstruction, 144, 151, 153–154, symptoms, 193–194 241, 249 treatment Bowel perforation, 143 antibiotics, 198–201 Brainerd diarrhea dietary support, 201–202 chronic secretory diarrhea, 321 mechanical methods, 202 microscopic colitis, 321 Bacteriotherapy, 46 sporadic idiopathic secretory diarrhea, 321 Bacteroides, 191, 349 478 Subject Index Bristol Stool Chart, 437 CD, see Celiac disease (CD) Brush-border membrane, 118, 162, 164 CD4 T-helper cells, 6, 64, 211, 373, 466 + Budesonide, 74–75, 98–99, 202, 366, 398, CD8 lymphocytes, 106, 212 447, 450 CDC, see Centers for Disease Control and Bulk-forming agents, 443, 448–449 Prevention (CDC) Ceftriaxone, 42, 291–293 Celiac disease (CD), 14, 96, 119, 122, 146, C 2+ − 198, 210–212, 301, 312, 316, 330, 342, Ca -activated Cl channel (CLCA), 344–345, 360–361, 365–366, 282–283, 288 369–370, 435 Caffeine, 77, 107, 337, 394, 396, 417, clinical presentation 427, 434 associated diseases, 217–218 Calcitonin atypical, extraintestinal manifestations, -secreting pancreatic endocrine tumors, 276 215–217 thyroid-secreting, 12, 257, 408 typical, gastrointestinal manifestations, Calcium channel blockers (CCB), 453 214–215 Calcium supplements, 167 complications Calprotectin, 21, 69, 198, 316–318, 347, 414, increased mortality rate, 222 436, 439 refractory celiac disease, 221–22 cAMP, see Cyclic adenosine monophosphate diagnosis, role of serology, 219 (cAMP) epidemiology, 210–211 Campylobacter, 4, 8, 14, 20–21, 35–36, 41, gluten free diet, 440 51, 65–66, 68, 348 pathophysiology
Load more

Recommended publications
  • Palliative Care Case of the Month
    PALLIATIVE CARE CASE OF THE MONTH “Treating Non-Infectious Diarrhea” by Robert Arnold, MD Volume 19, No. 98 August, 2019 Case 1: Mr. Jones is a 58-year-old man with short gut Three drugs are used because of their ability to slow down the syndrome. Palliative Care was consulted for goals of care, gut, allowing for more time for absorption of intestinal fluids a however quickly it became clear uncontrolled diarrhea was a decrease of diarrhea. The most well-know is loperamide, a larger priority. He said having to change the bag every few hours synthetic opiate which has minimal absorption. The dosing is 4 completely interfered with his living a normal life. He said, “I’d mg after one’s first bowel movement and then 2 mg after every rather die than have all of this diarrhea.” unformed stool, up to 16 mg (in palliative care patients there is some data for use up to 54 mg).9, 10 Loperamide should be Case 2: A 62-year-old woman with non-small cell lung cancer continued for 12 hours after diarrhea is stopped. Adverse effects is receiving immunotherapy. She has done quite well but is include mostly constipation, abdominal cramps, nausea and distressed by her diarrhea. She tried Lomotil and Imodium but rarely CNS effects like fatigue or dizziness. Cases of torsades de neither worked. When seeing her palliative care doctor, she said, pointes and death have been reported with higher than “It isn’t worth treating my cancer if I can’t live a normal life.” 9 recommended doses.
    [Show full text]
  • Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A
    Naher et al. Clinical Phytoscience (2019) 5:15 https://doi.org/10.1186/s40816-019-0109-z ORIGINAL CONTRIBUTION Open Access Anti-diarrheal activity and brine shrimp lethality bioassay of methanolic extract of Cordyline fruticosa (L.) A. Chev. leaves Sharmin Naher1*, Md. Abdullah Aziz1, Mst. Irin Akter2, S. M. Mushiur Rahman1, Sadiur Rahman Sajon1 and Kishor Mazumder1,3 Abstract Background: Cordyline fruticosa (L.) A. Chev. (Asparagaceae) is a plant which is traditionally used for the treatment of cough, bloody cough, diarrhea, dysentery, high fever, difficulties in urine, bloody urine, small pox, madness, skin eruptions, joint pains, rheumatic bone pains, sore throat, neck pain, bleeding hemorrhoids and inflammation in the digestive tract. Therefore, the present work aims to investigate the antidiarrheal and cytotoxic activities of methanolic extract of Cordyline fruticosa leaves in mice and brine shrimp, respectively. Methods: The effects of the methanol extract of Cordyline fruticosa leaves (MCFL) on castor oil-induced diarrhea, magnesium sulphate induced diarrhea and charcoal meal test in mice were investigated. In addition, brine shrimp lethality bioassay method was used to evaluate cytotoxic activity of MCFL. Results: In castor oil induced diarrheal test, MCFL at the dose of 200, 400 and 800 mg/kg body weight significantly (∗P< 0.05, versus control) and dose-dependently reduced the frequency of diarrhea. The frequency of magnesium sulphate-induced diarrhea was significantly reduced by MCFL at the dose of with 800 mg/kg. In the charcoal meal test, the extract at the dose of 400 and 800 mg/kg body weight significantly (∗P< 0.05) reduced the distance travelled by charcoal along the intestinal tract when compare with control.
    [Show full text]
  • Chronic Diarrhea
    Chronic Diarrhea Barbara McElhanon, MD Subra Kugathasan, MD Emory University School of Medicine 2013 Resident Education Series Reviewed by Edward Hoffenberg, MD of the Professional Education Committee Case • A 15 year old boy with PMH of obesity, anxiety disorder & ADHD presents with 3 months of non-bloody loose stool 5-15 times/day and diffuse abdominal pain that is episodically severe Case - History • Wellbutrin was stopped prior to the onset of her symptoms and her Psychiatrist was weaning Cymbalta • After stopping Cymbalta, she went to Costa Rica for a month long medical mission trip • Started having symptoms of abdominal pain and diarrhea upon return from her trip. • Ingestion of local Georgia creek water, but after her symptoms had started • Subjective fever x 4 days Case - Lab work by PCP • At onset of illness: – + occult blood in stool – + stool calprotectin (a measure of inflammation in the colon) – Negative stool WBC – Negative stool culture – Negative C. difficile – Negative ova & parasite study – Negative giardia antigen – Normal CBC with diff, Complete metabolic panel, CRP, ESR Case - History • Non-bloody diarrhea and abdominal pain continues • No relation to food • No fevers • No weight loss • Normal appetite • No night time occurrences • No other findings on ROS • No sick contacts Case – Work-up prior to visit Labs Imaging and Procedures • MRI enterography (MRI of the • Fecal occult blood, stool abdomen/pelvis with special cuts calprotectin, stool WBC, stool to evaluate the small bowel) culture, stool O&P, stool giardia
    [Show full text]
  • A Pediatrician's Guide to Constipation
    5/8/2018 Pediatric Upsies, Downsies and Oopsies – Diarrhea and Constipation GLENN DUH, M.D. PEDIATRIC GASTROENTEROLOGY KP DOWNEY (TRI-CENTRAL) I have nothing to disclose Objectives Identify the pertinent history information regarding the symptoms of diarrhea, constipation and rectal bleeding. Identify the “red flags“ associated with symptoms of constipation, and diarrhea and rectal bleeding. Describe indicate the workup/treatment/ management of diarrhea, constipation and rectal bleeding. 1 5/8/2018 First things first…what do you mean by “diarrhea”? Stools too soft or loose? Watery stools? Too much coming out? Undigested food in the stools? Soiling accidents with creamy peanut buttery poop in the underwear? Pooping too many times a day? Waking up at night to defecate? Do not assume that we all use the word the same way! First things first…what do you mean by “constipation”? Stools too hard? Bleeding? No poop for a week? Sits on toilet all day and nothing comes out? Stomachaches? KUB showing colon overstuffed with stuff? Do not assume that we all use the word the same way! It’s kind of gross to talk or think about this… 2 5/8/2018 Yummy… Diarrhea NOW THAT WE’VE LOOSENED THINGS UP A BIT…. What is diarrhea? Definition with numbers 3 or more loose stools a day > 10 mL/kg or > 200 grams of stools per day (not sure how one figures this one in the office) Longer than 14 days – chronic diarrhea The “eyeball” test If it looks like a duck, quacks like a duck, waddles like a duck… It doesn’t look like something else 3 5/8/2018 Acute vs.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Western Judicial Circuit Felony Drug Court
    Western Judicial Circuit Felony Drug Court (Athens-Clarke and Oconee Counties) PARTICIPANT HANDBOOK This handbook belongs to: 325 E. Washington Street, Suite 210 Athens, Georgia 30601 (706) 208-7078 (706) 613-3179 (fax) Table of Contents Welcome 3 Overview 4-5 Confidentiality 5 Treatment 5 Program Phases 6-10 Commencement 11 Program Rules 12-14 Program Fees 15 The Drug Court Team 15 Staffings 15 Court Appearances 16 Incentives 17 Sanctions and Treatment Responses 17 Termination 18 Drug/Chemical Testing 19 Prohibited Drugs/Permitted Medications 20-27 Travel/Leave Requests 27 Compliance & Home Visits/Job Checks, Searches 28 Search Requirements 28 Commencement Ceremony 29 Conclusion 29 Important Phone Numbers 30 Community Resources 31 Attachment I: Random Drug Screen Policy Attachment II: Urine Abstinence Testing/Incidental Alcohol Exposure Contract (original signed copy on file with Felony Drug Court) Attachment III: Emergency On-call Telephone Policy Attachment IV: Felony Drug Court Contract 2 Welcome to the Western Judicial Circuit Felony Drug Court! This Handbook was designed to answer your questions and provide specific information about what you must do in order to successfully complete the requirements of the Western Judicial Circuit Felony Drug Court Program. As a participant, you are expected to follow the instructions found in this Handbook, as well as the instructions of the Felony Drug Court Judge, Staff, and Treatment Provider. You will also be expected to comply with the treatment plan developed for you by your Treatment Provider. This handbook is not exhaustive and there is no possible way to make it complete and detailed to answer every question or situation that arises.
    [Show full text]
  • Sydney Medical Program Smp2014
    1! SYDNEY MEDICAL PROGRAM SMP2014 LEARNING TOPICS Stage 2 BLOCK 9: Gastroenterology and Nutrition Copyright © 2014 Sydney Medical Program, University of Sydney Compiled by P. Romo and S. Hewson for SUMS 2! CONTENTS • 9.01 – A persistent pain // Peptic ulcer 3 1. Upper gastrointestinal structures 4 2. Upper gastrointestinal motility 5 3. Vomiting 6 4. Gastric secretion 7 5. Causes of upper gastrointestinal bleeding 10 6. Complications of non-steroidal anti-inflammatory drugs 11 7. Early treatment of peptic ulcer 13 8. Medical evaluation in the aged 15 • 9.02 – I’m not a hundred per cent // Coeliac disease 16 1. Function of exocrine pancreas 17 2. Digestion 19 3. Nutrient absorption and transport 20 4. Nutritional approaches to GI disease 21 5. Vitamin and trace metal absorption 24 6. Mechanisms of diarrhoea 25 7. Mucosal immunity 26 8. Spectrum of coeliac disease 27 • 9.03 – Small and sickly // Failure to thrive in infancy 28 1. Normal nutrition in the first 12 months 29 2. Protein-energy malnutrition 31 3. Lactose intolerance 33 4. Understanding failure to thrive 34 5. Causes of diarrhoea 36 6. Management of acute diarrhoea 38 7. Infectious diarrhoea 41 8. Large bowel function 43 • 9.04 – My eyes look yellow // Gallstones 44 1. Bile secretion 45 2. Composition and formation of gallstones 46 3. Mechanisms of abdominal pain 48 4. Psychosocial issues in care of the older person 50 5. Therapeutic options in biliary disease 52 6. Antibiotic treatment in abdominal sepsis 54 • 9.05 – My pain is getting worse // Liver disease/Hep B 56 1.
    [Show full text]
  • (Promax-C) on Castor Oil-Induced Diarrhea in Mice
    World Journal of Advanced Research and Reviews, 2020, 07(03), 194–203 World Journal of Advanced Research and Reviews e-ISSN: 2581-9615, Cross Ref DOI: 10.30574/wjarr Journal homepage: https://www.wjarr.com (RESEARCH ARTICLE) Effects of hydroethanolic extract of Cameroonian propolis (Promax-c) on castor oil- induced diarrhea in mice Michel Archange Fokam Tagne 1, *, Paul Aimé Noubissi 2, Keya Jeremie Teddine Tchoblaouna 1, Gaëtan Olivier Fankem 3, Yaouke Rékabi 1, Hypolyte Akaou 1 and Fernand-Nestor Tchuenguem Fohouo 1, 1 Department of Biological Sciences, Faculty of Science, University of Ngaoundere, Cameroon. 2 Department of Zoology and Animal Physiology, Faculty of Science, University of Buea, Cameroon. 3 Animal Physiology Laboratory, Faculty of Science, University of Yaoundé I, Cameroon. Publication history: Received on 03 September 2020; revised on 14 September 2020; accepted on 17 September 2020 Article DOI: https://doi.org/10.30574/wjarr.2020.7.3.0336 Abstract The aim of our work was to evaluate the effect of hydroethanolic extract of Cameroonian propolis (Promax-c) on castor oil-induced diarrhea in mice. Diarrhea was induced in mice by oral administration 0.5 mL of castor oil in all mice. To determine the effective doses, each mouse received, 30 minutes after the administration of castor oil, one of the single oral doses of Promax-c: 0, 37.5, 75, 150, and 300 mg/kg bw. The mass and frequency of stool were measured and recorded per hour for five hours. The effect of Promax-c on the intestinal motility was evaluated by measuring the distance traveled by the charcoal meal in thirty minutes.
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • MSIR (Morphine) Medical Facts from Drugs.Com 04/07/2015
    MSIR (morphine) medical facts from Drugs.com 04/07/2015 Browse all medications A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Advanced Search Phonetic Search Drugs A-Z Pill Identifier Interactions Checker News Health Professionals Q & A Mednotes Apps Home → Conditions → Pain → MSIR Print Share Sign In or Register MSIR Related Information Availability Pregnancy Category Generic Name: morphine (MOR feen) Prescription only Risk cannot be ruled out Brand Name: AVINza, Kadian, MS Contin CSA Schedule WADA Class High potential for abuse Anti-Doping Classification Overview Side Effects Dosage Interactions More Reviews Average User Rating Reduce Nerve Pain Now Don't Let Neuropathy Symptoms Slow You Down. Get A Free Trial 1 User Review 9.0 Rate it! Now! Manufacturer What is MSIR (morphine)? Purdue Pharma LP Morphine is an opioid pain medication. An opioid is sometimes called a narcotic. Drug Class Morphine is used to treat moderate to severe Narcotic analgesics pain. Short-acting morphine is taken as needed for pain. Related Drugs The extended-release form of this medicine is Chronic Pain for around-the-clock treatment of pain. This tramadol form of morphine is not for use on an as- oxycodone needed basis for pain. Cymbalta Percocet Morphine is not for treating short-term pain just fentanyl after surgery unless you were already taking morphine morphine before the surgery. duloxetine methadone Morphine may also be used for purposes not Dilaudid listed in this medication guide. OxyContin Ultram More... Pain What is the most important information I should know about tramadol MSIR (morphine)? oxycodone naproxen You should not take this medicine if you have severe asthma or breathing problems, a blockage in acetaminophen your stomach or intestines, or a bowel obstruction called paralytic ileus.
    [Show full text]
  • Diarrhea & Malabsorption
    ھذه اﻟﻣﺣﺎﺿرة ھﻲ ﺗﻛرﯾم ﻟﻛل ﻣن ﯾﻌﻣل وﻻ ﯾﻛرّم،ﻟﻛل ﻣن ﯾﻌﻣل ﺑﺎﻟﺧﻔﺎء،ﻟﻛل اﯾﺎدي ﺗدﻓﻌﻧﺎ ﻣن ظﮭورﻧﺎ ﻻ ﻧرى وﺟوه اﺻﺣﺎﺑﮭﺎ Please note: This work is based on male slides except few points will appear pink Diarrhea & Malabsorption Content Explanation Notes Important ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ Objectives and there answers from Dr slides ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ LONG LIVE ABOOD LONG LIVE ABOOD ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ Understand the physiology of fluid in small intestine ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ● 1.5 liter food LONG LIVE ABOOD ● 7 liters secretions and reabsorbed in small intestine LONG LIVE ABOOD ● 1.4 reabsorbed in large intestine ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ Describe the pathophysiology and causes of various types of diarrhea LONG LIVE ABOOD ● Secretory: Normal stool osmotic gap {bacterial toxin ( E. coli , cholera) LONG LIVE ABOOD Endocrine tumours} ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ● osmotic: osmotic gap is high , {Malabsorption, osmotic laxatives} ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ● Exudative: blood and pus in the stool, { inflammatory bowel diseases, LONG LIVE ABOOD and invasive infections} LONG LIVE ABOOD ● Motility-related: {Irritable bowel syndrome (IBS)} ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ LONG LIVE ABOOD Define acute diarrhea and enumerate its common causes LONG LIVE ABOOD ● Less than 2 weeks ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ● infections (viruses, bacteria, helminths, and protozoa). Food poisoning ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ LONG LIVE ABOOD LONG LIVE ABOOD ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ Define chronic diarrhea and enumerate its common causes ❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤❤ ● More than one month LONG LIVE
    [Show full text]
  • Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
    IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 1/89 PROTOCOL TITLE: EFFICACY OF DIOSMECTITE (SMECTA®) IN THE SYMPTOMATIC TREATMENT OF ACUTE DIARRHOEA IN ADULTS. A MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY STUDY PROTOCOL STUDY number: F-FR-00250-105 (Diosmectite- BN 00250) EudraCT number: n° 2015-001138-10 Final Version (with Amendment No. 4): 07 January 2019 Sponsor’s Medically Responsible Person: Study Sponsor: PPD Ipsen Pharma SAS PPD 65 quai Georges Gorse Ipsen Pharma SAS 92100 Boulogne-Billancourt, France 65 quai Georges Gorse Tel: PPD 92100 Boulogne-Billancourt, France Fax: PPD Tel: PPD Fax: PPD Monitoring Office: and/or CRO Co-ordinating Investigator: PPD PPD PPD Délégation à la Recherche Ipsen Pharma SAS Centre Hospitalier Régional Universitaire 65 quai Georges Gorse de Lille 92100 Boulogne-Billancourt, France 2, avenue Oscar Lambret, Tel: PPD 59037 Lille, France Cedex Fax: PPD Tel: PPD Fax: PPD Pharmacovigilance/Emergency Contact: PPD Ipsen Innovation, ZI de Courtaboeuf - 5 avenue du Canada - 91940 Les Ulis - France Tel: PPD Tel: PPD – PPD For SAEs reporting: Fax: PPD Email: PPD Persons supplied with this information must understand that it is strictly confidential. Information contained herein cannot be disclosed, submitted for publication or used for any purpose other than that contemplated herein without the sponsor’s prior written authorisation. IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 2/89 INVESTIGATOR’S AGREEMENT Investigator Agreement and Signature: I have read and agree to Protocol F-FR-00250-105 entitled Efficacy of the diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults.
    [Show full text]